{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:18:33Z","timestamp":1791469113320,"version":"4.3.4"},"reference-count":156,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"2024 Research, Community Service, and Innovation (PPMI 2024) Program, School of Pharmacy, Institut Teknologi Bandung","award":["31\/IT1.C10\/SK-KU\/2024"],"award-info":[{"award-number":["31\/IT1.C10\/SK-KU\/2024"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Sciences"],"abstract":"<jats:p>Breast cancer is the most prevalent cancer in women. Anthracyclines are commonly used as the first line of treatment, often combined with other agents, including trastuzumab. Despite their efficacy, both drugs pose a risk of cardiotoxicity, which may impair patients\u2019 quality of life (QoL) and hinder treatment persistence. Anthracycline-induced cardiotoxicity is dose-dependent and generally irreversible, whereas trastuzumab is associated with potentially reversible cardiac dysfunction. This review discusses the risk factors and biological mechanisms underlying chemotherapy-induced cardiotoxicity in breast cancer and explores effective strategies for prevention and treatment. It has been demonstrated that several cardioprotective strategies, such as treatments with angiotensin-converting enzyme inhibitors (ACEis), angiotensin receptor blockers (ARBs), beta-blockers, and dexrazoxane, can help lessen cardiotoxic effects. A better understanding of cardioprotective strategies may help optimize cancer treatment without compromising cardiovascular function.<\/jats:p>","DOI":"10.3390\/medsci13030130","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T14:51:46Z","timestamp":1755183106000},"page":"130","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cardiotoxicity in Breast Cancer Therapy: Risks, Mechanisms, and Prevention Strategies"],"prefix":"10.3390","volume":"13","author":[{"given":"Annisa Eka","family":"Fitrianti","sequence":"first","affiliation":[{"name":"Master\u2019s Program in Pharmacy, School of Pharmacy, Institut Teknologi Bandung, Bandung 40132, Indonesia"},{"name":"Department of Pharmacy, Dr. Hasan Sadikin General Hospital, Bandung 40161, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadea Olyvia","family":"Wardani","sequence":"additional","affiliation":[{"name":"Master\u2019s Program in Pharmacy, School of Pharmacy, Institut Teknologi Bandung, Bandung 40132, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astri","family":"Astuti","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Dr. Hasan Sadikin General Hospital, Bandung 40161, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9879-6112","authenticated-orcid":false,"given":"Kusnandar","family":"Anggadiredja","sequence":"additional","affiliation":[{"name":"Department of Pharmacology\u2014Clinical Pharmacy, Institut Teknologi Bandung, Bandung 40132, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia","family":"Amalia","sequence":"additional","affiliation":[{"name":"Department of Pharmacology\u2014Clinical Pharmacy, Institut Teknologi Bandung, Bandung 40132, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risani Andalasia","family":"Putri","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Dharmais Cancer Hospital, Jakarta 11420, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1264-9558","authenticated-orcid":false,"given":"Zulfan","family":"Zazuli","sequence":"additional","affiliation":[{"name":"Department of Pharmacology\u2014Clinical Pharmacy, Institut Teknologi Bandung, Bandung 40132, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"ref_1","unstructured":"Loscalzo, J., and Fauci, A. (2022). Breast cancer. Harrison\u2019s Principles of Internal Medicine, McGraw-Hill Education. [21st ed.]. Chapter 75."},{"key":"ref_2","unstructured":"(2025, January 08). Global Cancer Observatory: Cancer Today. Available online: https:\/\/gco.iarc.who.int\/today."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","article-title":"Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100,000 women in 123 randomised trials","volume":"379","author":"Peto","year":"2012","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/eci.12589","article-title":"Update on cardiotoxicity of anti-cancer treatments","volume":"46","author":"Rosa","year":"2016","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/ncponc1045","article-title":"Is trastuzumab associated with adverse cardiac effects in patients with breast cancer?","volume":"5","author":"Ewer","year":"2008","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10549-014-3029-0","article-title":"Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival","volume":"146","author":"Wang","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1200\/JCO.2004.01.120","article-title":"Clinical Cardiac Tolerability of Trastuzumab","volume":"22","author":"Perez","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_8","unstructured":"Kementerian Kesehatan Republik Indonesia (2018). Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07\/MENKES\/414\/2018 tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Kanker Payudara, Kementerian Kesehatan Republik Indonesia. Available online: https:\/\/kemkes.go.id\/app_asset\/file_content_download\/170115800565659c7587dac8.09513662.pdf."},{"key":"ref_9","unstructured":"World Health Organization (2025, January 08). Breast Cancer. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jare.2021.07.012","article-title":"Epidemiological and sociodemographic transitions of female breast cancer incidence, death, case fatality and DALYs in 21 world regions and globally, from 1990 to 2017: An Age-Period-Cohort Analysis","volume":"37","author":"Mubarik","year":"2022","journal-title":"J. Adv. Res."},{"key":"ref_11","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13058-016-0759-4","article-title":"The genetics of breast cancer risk in the post-genome era: Thoughts on study design to move past BRCA and towards clinical relevance","volume":"18","author":"Skol","year":"2016","journal-title":"Breast Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.7150\/ijbs.21635","article-title":"Risk Factors and Preventions of Breast Cancer","volume":"13","author":"Sun","year":"2017","journal-title":"Int. J. Biol. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Shaath, H., and Elango, R. (2021). Molecular Classification of Breast Cancer Utilizing Long Non-Coding RNA (lncRNA) Transcriptomes Identifies Novel Diagnostic lncRNA Panel for Triple-Negative Breast Cancer. Cancers, 13.","DOI":"10.3390\/cancers13215350"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Zubair, M., and Wang, S. (2021). Advanced Approaches to Breast Cancer Classification and Diagnosis. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.632079"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3816\/CBC.2004.n.011","article-title":"HER2 Amplification Ratios by Fluorescence In Situ Hybridization and Correlation with Immunohistochemistry in a Cohort of 6556 Breast Cancer Tissues","volume":"5","author":"Owens","year":"2004","journal-title":"Clin. Breast Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2\/neu Oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1158\/1055-9965.EPI-17-0627","article-title":"Differences in Breast Cancer Survival by Molecular Subtypes in the United States","volume":"27","author":"Howlader","year":"2018","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ramamoorthy, P., and Dandawate, P. (2021). Celastrol and Triptolide Suppress Stemness in Triple Negative Breast Cancer: Notch as a Therapeutic Target for Stem Cells. Biomedicines, 9.","DOI":"10.3390\/biomedicines9050482"},{"key":"ref_20","unstructured":"(2025, January 08). Breast Cancer Treatment (PDQ\u00ae)\u2014Health Professional Version, Available online: https:\/\/www.cancer.gov\/types\/breast\/hp\/breast-treatment-pdq."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/S1470-2045(21)00288-6","article-title":"Trastuzumab for early-stage, HER2-positive breast cancer: A meta-analysis of 13,864 women in seven randomised trials","volume":"22","author":"Bradley","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.2174\/092986709788803312","article-title":"Doxorubicin: The Good, the Bad and the Ugly Effect","volume":"16","author":"Carvalho","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","article-title":"Anthracycline Chemotherapy and Cardiotoxicity","volume":"31","author":"McGowan","year":"2017","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_24","first-page":"78","article-title":"Molecular mechanisms of anthracyclines action","volume":"60","author":"Czyz","year":"2006","journal-title":"Postep. Hig. Med. Dosw."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e000665","DOI":"10.1161\/JAHA.113.000665","article-title":"Cancer Therapy\u2013Induced Cardiotoxicity: Basic Mechanisms and Potential Cardioprotective Therapies","volume":"3","author":"Hahn","year":"2014","journal-title":"J. Am. Heart Assoc."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Iqbal, N., and Iqbal, N. (2014). Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol. Biol. Int., 2014.","DOI":"10.1155\/2014\/852748"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4161\/cc.4.1.1360","article-title":"HER2-targeting Antibodies Modulate the Cyclin-dependent Kinase Inhibitor p27Kip1 via Multiple Signaling Pathways","volume":"4","author":"Le","year":"2005","journal-title":"Cell Cycle"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Vu, T., and Claret, F.X. (2012). Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer. Front. Oncol., 2.","DOI":"10.3389\/fonc.2012.00062"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)60028-2","article-title":"2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial","volume":"369","author":"Smith","year":"2007","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer","volume":"353","author":"Procter","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1200\/JCO.2006.06.5391","article-title":"Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide with Docetaxel Plus Cyclophosphamide as Adjuvant Therapy for Operable Breast Cancer","volume":"24","author":"Jones","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","article-title":"Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): A randomised controlled superiority trial with a parallel HER2-negative cohort","volume":"375","author":"Gianni","year":"2010","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2017.35.15_suppl.511","article-title":"Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC)","volume":"35","author":"Tolaney","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","article-title":"Breast Cancer","volume":"22","author":"Gradishar","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1470-2045(21)00758-0","article-title":"Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: A patient-level meta-analysis of 7030 women from four randomised trials","volume":"23","author":"Bradley","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: Abemaciclib in Combination with Fulvestrant in Women with HR+\/HER2\u2212 Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor\u2013Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy\u2014MONARCH 2","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib Combined with Endocrine Therapy for the Adjuvant Treatment of HR+, HER2\u2212, Node-Positive, High-Risk, Early Breast Cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant Olaparib for Patients with BRCA1\u2014Or BRCA2\u2014Mutated Breast Cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jnci\/djp440","article-title":"Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention","volume":"102","author":"Albini","year":"2010","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"27","author":"Plana","year":"2014","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.5603\/KP.2016.0156","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines","volume":"74","author":"Zamorano","year":"2016","journal-title":"Pol. Heart J. (Kardiol. Pol.)"},{"key":"ref_48","first-page":"59","article-title":"Chemotherapy-induced Cardiotoxicity","volume":"8","author":"Florescu","year":"2013","journal-title":"Maedica"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00002018-200022040-00002","article-title":"Cardiotoxicity of Chemotherapeutic Agents","volume":"22","author":"Pai","year":"2000","journal-title":"Drug Saf."},{"key":"ref_50","first-page":"8","article-title":"Chemotherapy Induced Cardiomyopathy: Pathogenesis, Monitoring and Management","volume":"11","author":"Shakir","year":"2009","journal-title":"J. Clin. Med. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jacc.2018.10.038","article-title":"ACC\/AATS\/AHA\/ASE\/ASNC\/HRS\/SCAI\/SCCT\/SCMR\/STS 2019 Appropriate Use Criteria for Multimodality Imaging in the Assessment of Cardiac Structure and Function in Nonvalvular Heart Disease","volume":"73","author":"Doherty","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_52","first-page":"140","article-title":"Global Longitudinal Strain Accuracy for Cardiotoxicity Prediction in a Cohort of Breast Cancer Patients During Anthracycline and\/or Trastuzumab Treatment","volume":"110","author":"Gripp","year":"2018","journal-title":"Arq. Bras. Cardiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","article-title":"Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation","volume":"28","author":"Cardinale","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","article-title":"Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy","volume":"109","author":"Cardinale","year":"2004","journal-title":"Circulation"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","article-title":"Early Increases in Multiple Biomarkers Predict Subsequent Cardiotoxicity in Patients with Breast Cancer Treated with Doxorubicin, Taxanes, and Trastuzumab","volume":"63","author":"Ky","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/CIRCIMAGING.112.973321","article-title":"Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated with Anthracyclines, Taxanes, and Trastuzumab","volume":"5","author":"Sawaya","year":"2012","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Dicato, M.A., and Van, C.E. (2013). Breast Cancer. Side Effects of Medical Cancer Therapy Prevention and Treatment, Springer. [2nd ed.].","DOI":"10.1007\/978-0-85729-787-7"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.1200\/JCO.2007.14.0657","article-title":"Reversibility of Trastuzumab Cardiotoxicity: Is the Concept Alive and Well?","volume":"25","author":"Ewer","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Smith, L.A., and Cornelius, V.R. (2010). Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials. BMC Cancer, 10.","DOI":"10.1186\/1471-2407-10-337"},{"key":"ref_60","first-page":"309","article-title":"Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management","volume":"66","author":"Curigliano","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1016\/j.amjcard.2013.08.026","article-title":"Review and Meta-Analysis of Incidence and Clinical Predictors of Anthracycline Cardiotoxicity","volume":"112","author":"Lotrionte","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"Layard","year":"1979","journal-title":"Ann. Intern. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrcardio.2015.65","article-title":"Cardiotoxicity of anticancer treatments: What the cardiologist needs to know","volume":"12","author":"Ewer","year":"2015","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10557-020-06941-x","article-title":"The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity","volume":"34","author":"Timm","year":"2020","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/jnci\/djs317","article-title":"Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study","volume":"104","author":"Bowles","year":"2012","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ctrv.2010.09.001","article-title":"Risk of cardiac dysfunction with trastuzumab in breast cancer patients: A meta-analysis","volume":"37","author":"Chen","year":"2011","journal-title":"Cancer Treat. Rev."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12032-016-0797-x","article-title":"Anthracycline- and trastuzumab-induced cardiotoxicity: A retrospective study","volume":"33","author":"Hamirani","year":"2016","journal-title":"Med. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamacardio.2019.2952","article-title":"Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity","volume":"4","author":"Oikonomou","year":"2019","journal-title":"JAMA Cardiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.clon.2022.05.001","article-title":"Global Longitudinal Strain for the Early Detection of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis","volume":"34","author":"Cocco","year":"2022","journal-title":"Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/CIRCULATIONAHA.122.059678","article-title":"High-Sensitivity Cardiac Troponin and the 2021 AHA\/ACC\/ASE\/CHEST\/SAEM\/SCCT\/SCMR Guidelines for the Evaluation and Diagnosis of Acute Chest Pain","volume":"146","author":"Sandoval","year":"2022","journal-title":"Circulation"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Sorodoc, V., and Sirbu, O. (2022). The Value of Troponin as a Biomarker of Chemotherapy-Induced Cardiotoxicity. Life, 12.","DOI":"10.3390\/life12081183"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1080\/14740338.2017.1351541","article-title":"Breast cancer treatment-induced cardiotoxicity","volume":"16","author":"Martel","year":"2017","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1200\/OP.23.00494","article-title":"Cardiotoxicity of Agents Used in Patients with Breast Cancer","volume":"20","author":"Zagami","year":"2024","journal-title":"JCO Oncol. Pr."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/annonc\/mds293","article-title":"Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines","volume":"23","author":"Curigliano","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40959-020-00081-9","article-title":"Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer","volume":"6","author":"Sardesai","year":"2020","journal-title":"Cardio-Oncology"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Esteban-Fern\u00e1ndez, A., Carvajal Estupi\u00f1an, J.F., Gavira-G\u00f3mez, J.J., Pernas, S., Moliner, P., Garay, A., S\u00e1nchez-Gonz\u00e1lez, \u00c1., Fern\u00e1ndez-Rozas, I., and Gonz\u00e1lez-Costello, J. (2021). Clinical Profile and Prognosis of a Real-World Cohort of Patients with Moderate or Severe Cancer Therapy-Induced Cardiac Dysfunction. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.721080"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1200\/JCO.2009.23.6950","article-title":"Independent Adjudication of Symptomatic Heart Failure with the Use of Doxorubicin and Cyclophosphamide Followed by Trastuzumab Adjuvant Therapy: A Combined Review of Cardiac Data from the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 Clinical Trials","volume":"28","author":"Russell","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)61094-6","article-title":"2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): An open-label, randomised controlled trial","volume":"382","author":"Goldhirsch","year":"2013","journal-title":"Lancet"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1200\/JCO.2007.13.5467","article-title":"Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel with or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial","volume":"26","author":"Perez","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"7811","DOI":"10.1200\/JCO.2005.02.4091","article-title":"Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab as Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2\u2013Overexpressing Breast Cancer: NSABP B-31","volume":"23","author":"Yothers","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1007\/s12282-014-0543-1","article-title":"Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer","volume":"21","author":"Neugut","year":"2014","journal-title":"Breast Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/j.ijcard.2008.11.145","article-title":"Left atrial intramural hematoma after percutaneous coronary intervention","volume":"141","author":"Solzbach","year":"2010","journal-title":"Int. J. Cardiol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10549-014-3253-7","article-title":"Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer","volume":"149","author":"Yu","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s10549-016-3823-y","article-title":"Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: A population-based study","volume":"157","author":"Gong","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Qiu, Y., and Jiang, P. (2023). Anthracycline-induced cardiotoxicity: Mechanisms, monitoring, and prevention. Front. Cardiovasc. Med., 10.","DOI":"10.3389\/fcvm.2023.1242596"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Rawat, P.S., and Jaiswal, A. (2021). Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed. Pharmacother., 139.","DOI":"10.1016\/j.biopha.2021.111708"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1161\/ATVBAHA.121.316697","article-title":"Cardiotoxicity of Cancer Treatments: Focus on Anthracycline Cardiomyopathy","volume":"41","author":"Nishi","year":"2021","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11864-020-00812-1","article-title":"Metabolic Aspects of Anthracycline Cardiotoxicity","volume":"22","author":"Russo","year":"2021","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1161\/CIRCRESAHA.122.321667","article-title":"Iron Metabolism in Cardiovascular Disease: Physiology, Mechanisms, and Therapeutic Targets","volume":"132","author":"Sawicki","year":"2023","journal-title":"Circ. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/nm0107-14","article-title":"In reply to \u201cCardiotoxicity of the cancer therapeutic agent imatinib mesylate\u201d","volume":"13","author":"Atallah","year":"2007","journal-title":"Nat. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Grazette","year":"2006","journal-title":"Nat. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41419-021-03614-x","article-title":"Regulated cell death pathways in doxorubicin-induced cardiotoxicity","volume":"12","author":"Christidi","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijcard.2008.01.043","article-title":"Adriamycin-induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure","volume":"134","author":"Lu","year":"2009","journal-title":"Int. J. Cardiol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.tox.2017.08.011","article-title":"Altered mitochondrial epigenetics associated with subchronic doxorubicin cardiotoxicity","volume":"390","author":"Ferreira","year":"2017","journal-title":"Toxicology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.yjmcc.2018.10.007","article-title":"HDAC6 inhibition protects cardiomyocytes against doxorubicin-induced acute damage by improving \u03b1-tubulin acetylation","volume":"124","author":"Song","year":"2018","journal-title":"J. Mol. Cell Cardiol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jaccao.2023.12.009","article-title":"Circulating MicroRNA as Biomarkers of Anthracycline-Induced Cardiotoxicity","volume":"6","author":"Boen","year":"2024","journal-title":"JACC CardioOncol\u3002"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"ElZarrad, M.K., and Mukhopadhyay, P. (2013). Trastuzumab Alters the Expression of Genes Essential for Cardiac Function and Induces Ultrastructural Changes of Cardiomyocytes in Mice. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0079543"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/002215540505300110","article-title":"Neuregulin Receptor ErbB2 Localization at T-tubule in Cardiac and Skeletal Muscle","volume":"53","author":"Hideho","year":"2005","journal-title":"J. Histochem. Cytochem."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Lin, M., and Xiong, W. (2022). The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.821663"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1158\/1535-7163.MCT-15-0741","article-title":"Trastuzumab, but Not Pertuzumab, Dysregulates HER2 Signaling to Mediate Inhibition of Autophagy and Increase in Reactive Oxygen Species Production in Human Cardiomyocytes","volume":"15","author":"Mohan","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s00395-016-0576-z","article-title":"ErbB2 signaling at the crossing between heart failure and cancer","volume":"111","author":"Vermeulen","year":"2016","journal-title":"Basic Res. Cardiol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1161\/CIRCRESAHA.109.205906","article-title":"The Vulnerability of the Heart as a Pluricellular Paracrine Organ","volume":"106","author":"Doggen","year":"2010","journal-title":"Circ. Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1161\/CIRCULATIONAHA.107.690487","article-title":"Role of Neuregulin-1\/ErbB Signaling in Cardiovascular Physiology and Disease","volume":"116","author":"Lemmens","year":"2007","journal-title":"Circulation"},{"key":"ref_105","first-page":"1","article-title":"The Roles of Neuregulin-1 in Cardiac Development, Homeostasis, and Disease","volume":"10","author":"Rupert","year":"2015","journal-title":"Biomark. Insights"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1042\/CS20200230","article-title":"Neuregulins: Protective and reparative growth factors in multiple forms of cardiovascular disease","volume":"134","author":"Geissler","year":"2020","journal-title":"Clin. Sci."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nm0502-459","article-title":"ErbB2 is essential in the prevention of dilated cardiomyopathy","volume":"8","author":"Crone","year":"2002","journal-title":"Nat. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"8880","DOI":"10.1073\/pnas.122249299","article-title":"Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy","volume":"99","author":"Erdmann","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1074\/jbc.M804570200","article-title":"Blockade of the erbB2 Receptor Induces Cardiomyocyte Death through Mitochondrial and Reactive Oxygen Species-dependent Pathways","volume":"284","author":"Gordon","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11010-006-9335-z","article-title":"Differential role of PI3K\/Akt pathway in the infarct size limitation and antiarrhythmic protection in the rat heart","volume":"297","year":"2007","journal-title":"Mol. Cell Biochem."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.tips.2015.03.005","article-title":"Anthracyclines\/trastuzumab: New aspects of cardiotoxicity and molecular mechanisms","volume":"36","author":"Rochette","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_112","first-page":"70","article-title":"Trastuzumab-induced cardiac dysfunction: A \u201cdual-hit\u201d","volume":"16","author":"Zeglinski","year":"2011","journal-title":"Exp. Clin. Cardiol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3892\/ol.2017.5557","article-title":"Targeting the Ras\/Raf\/MEK\/ERK pathway in hepatocellular carcinoma","volume":"13","author":"Yang","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/02699050500284218","article-title":"The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions","volume":"24","author":"Yoon","year":"2006","journal-title":"Growth Factors"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"6255","DOI":"10.1038\/sj.onc.1205794","article-title":"Anti-tumor activity of GW572016: A dual tyrosine kinase inhibitor blocks EGF activation of EGFR\/erbB2 and downstream Erk1\/2 and AKT pathways","volume":"21","author":"Xia","year":"2002","journal-title":"Oncogene"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pharmthera.2018.06.017","article-title":"Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors","volume":"192","author":"Bronte","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bjc.6601401","article-title":"Angiogenesis inhibitors in clinical development; where are we now and where are we going?","volume":"90","author":"Eskens","year":"2004","journal-title":"Br. J. Cancer"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2006.10.4976","article-title":"Congestive Heart Failure in Older Women Treated with Adjuvant Anthracycline Chemotherapy for Breast Cancer","volume":"25","author":"Pinder","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1200\/JCO.2015.65.1505","article-title":"Breast Cancer Therapy\u2013Related Cardiac Dysfunction in Adult Women Treated in Routine Clinical Practice: A Population-Based Cohort Study","volume":"34","author":"Thavendiranathan","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1002\/cam4.1886","article-title":"Doxorubicin-induced heart failure in cancer patients: A cohort study based on the Korean National Health Insurance Database","volume":"7","author":"Kim","year":"2018","journal-title":"Cancer Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"178","DOI":"10.4048\/jbc.2013.16.2.178","article-title":"Early Cardiac Function Monitoring for Detection of Subclinical Doxorubicin Cardiotoxicity in Young Adult Patients with Breast Cancer","volume":"16","author":"Chun","year":"2013","journal-title":"J. Breast Cancer"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrc1408","article-title":"Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms","volume":"4","author":"Calle","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0140-6736(08)60269-X","article-title":"Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies","volume":"371","author":"Renehan","year":"2008","journal-title":"Lancet"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1200\/JCO.2016.67.4846","article-title":"Obesity as a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis","volume":"34","author":"Guenancia","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Kabor\u00e9, E.G., and Guenancia, C. (2019). Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study. PLoS Med., 16.","DOI":"10.1371\/journal.pmed.1002989"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Cai, Z., and Xie, Q. (2020). S100A8\/A9 in Myocardial Infarction: A Promising Biomarker and Therapeutic Target. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.603902"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1200\/JCO.2017.72.4211","article-title":"Preexisting Cardiovascular Risk and Subsequent Heart Failure Among Non-Hodgkin Lymphoma Survivors","volume":"35","author":"Salz","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: A position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","article-title":"Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients with Breast Cancer","volume":"73","author":"Guglin","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.breast.2017.10.010","article-title":"Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction & heart failure during anthracycline chemotherapy \u00b1 trastuzumab","volume":"37","author":"Gujral","year":"2018","journal-title":"Breast"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1016\/j.jacc.2012.07.067","article-title":"Effect of Statin Therapy on the Risk for Incident Heart Failure in Patients with Breast Cancer Receiving Anthracycline Chemotherapy","volume":"60","author":"Seicean","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","article-title":"Enalapril and Carvedilol for Preventing Chemotherapy-Induced Left Ventricular Systolic Dysfunction in Patients With Malignant Hemopathies","volume":"61","author":"Bosch","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): A 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.ijcard.2012.06.023","article-title":"Protective effects of nebivolol against anthracycline-induced cardiomyopathy: A randomized control study","volume":"167","author":"Kaya","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/postgradmedj-2015-133535","article-title":"Cardioprotective role of \u03b2-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: A systematic review and meta-analysis","volume":"91","author":"Yun","year":"2015","journal-title":"Postgrad. Med. J."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of High-Dose Chemotherapy\u2013Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1002\/cam4.3956","article-title":"Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin","volume":"10","author":"Lee","year":"2021","journal-title":"Cancer Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"PD5-03","DOI":"10.1158\/1538-7445.SABCS15-PD5-03","article-title":"Abstract PD5-03: Prophylactic beta blockade preserves left ventricular ejection fraction in HER2-overexpresssing breast cancer patients receiving trastuzumab: Primary results of the MANTICORE randomized controlled trial","volume":"76","author":"Pituskin","year":"2021","journal-title":"Cancer Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.cardfail.2012.06.416","article-title":"Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia","volume":"18","author":"Tolba","year":"2012","journal-title":"J. Card. Fail."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","article-title":"Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy","volume":"48","author":"Kalay","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","article-title":"Angiotensin II\u2013Receptor Inhibition with Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients with Early Breast Cancer","volume":"2","author":"Boekhout","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/0006-2952(95)00218-O","article-title":"A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane)","volume":"50","author":"Hasinoff","year":"1995","journal-title":"Biochem. Pharmacol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.1158\/0008-5472.CAN-07-1649","article-title":"Topoisomerase II\u03b2\u2013Mediated DNA Double-Strand Breaks: Implications in Doxorubicin Cardiotoxicity and Prevention by Dexrazoxane","volume":"67","author":"Lyu","year":"2007","journal-title":"Cancer Res."},{"key":"ref_147","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1200\/JCO.2001.19.5.1444","article-title":"Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome-Encapsulated Doxorubicin and Cyclophosphamide Compared with Conventional Doxorubicin and Cyclophosphamide in a Randomized, Multicenter Trial of Metastatic Breast Cancer","volume":"19","author":"Batist","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.ejca.2015.07.031","article-title":"Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: A Bayesian network meta-analysis","volume":"51","author":"Yamaguchi","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"610","DOI":"10.21037\/cdt-20-165","article-title":"The use of cardiovascular magnetic resonance as an early non-invasive biomarker for cardiotoxicity in cardio-oncology","volume":"10","author":"Burrage","year":"2020","journal-title":"Cardiovasc. Diagn. Ther."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/eurjcn\/zvab057","article-title":"Quality of life in breast cancer patients with cancer treatment-related cardiac dysfunction: A qualitative study","volume":"21","author":"Koop","year":"2022","journal-title":"Eur. J. Cardiovasc. Nurs."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Murg, S.I., and Mati\u0219, L. (2024). Cardiotoxicity in Breast Cancer: Impact of Clinical Classifications and Treatment on Heart Health. Cancers, 16.","DOI":"10.3390\/cancers16244281"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1007\/s00392-018-1386-0","article-title":"Recovery from left ventricular dysfunction was associated with the early introduction of heart failure medical treatment in cancer patients with anthracycline-induced cardiotoxicity","volume":"108","author":"Ohtani","year":"2019","journal-title":"Clin. Res. Cardiol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","article-title":"Reversibility of Trastuzumab-Related Cardiotoxicity: New Insights Based on Clinical Course and Response to Medical Treatment","volume":"23","author":"Ewer","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jaccao.2019.08.003","article-title":"Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast Cancer","volume":"1","author":"Macedo","year":"2019","journal-title":"JACC CardioOncol"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American society of clinical oncology clinical practice guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J. Clin. Oncol."}],"container-title":["Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3271\/13\/3\/130\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:27:10Z","timestamp":1760034430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3271\/13\/3\/130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":156,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["medsci13030130"],"URL":"https:\/\/doi.org\/10.3390\/medsci13030130","relation":{},"ISSN":["2076-3271"],"issn-type":[{"value":"2076-3271","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]}}}